U.S. License Holder:
UCB Inc.
Date of License:
April-22-2008
Last Update:
Nov-15-2024
FDA-Approved Indications
CIMZIA (certolizumab pegol) is a tumor necrosis factor (TNF) blocker indicated for:
Reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy;
Treatment of adults with moderately to severely active rheumatoid arthritis;
Treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older;
Treatment of adult patients with active psoriatic arthritis;
Treatment of adults with active ankylosing spondylitis;
Treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation;
Treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
U.S. Patent Litigations